Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain
Beatriz Poblador‐Plou, Jonás Carmona‐Pírez, Ignatios Ioakeim‐Skoufa, Antonio Poncel-Falcó, Kevin Bliek-Bueno, Mabel Cano-del Pozo, Luís Andrés Gimeno-Feliú, Francisca González‐Rubio, Mercedes Aza‐Pascual‐Salcedo, Ana Cristina Bandrés-Liso, Jesús Díez‐Manglano, Javier Marta-Moreno, Sara Mucherino, Antonio Gimeno‐Miguel, Alexandra Prados‐Torres, EpiChron Group
Abstract
We aimed to analyze baseline socio-demographic and clinical factors associated with an increased likelihood of mortality in men and women with coronavirus disease (COVID-19). We conducted a retrospective cohort study (PRECOVID Study) on all 4412 individuals with laboratory-confirmed COVID-19 in Aragon, Spain, and followed them for at least 30 days from cohort entry. We described the socio-demographic and clinical characteristics of all patients of the cohort. Age-adjusted logistic regressions models were performed to analyze the likelihood of mortality based on demographic and clinical variables. All analyses were stratified by sex. Old age, specific diseases such as diabetes, acute myocardial infarction, or congestive heart failure, and dispensation of drugs like vasodilators, antipsychotics, and potassium-sparing agents were associated with an increased likelihood of mortality. Our findings suggest that specific comorbidities, mainly of cardiovascular nature, and medications at the time of infection could explain around one quarter of the mortality in COVID-19 disease, and that women and men probably share similar but not identical risk factors. Nonetheless, the great part of mortality seems to be explained by other patient- and/or health-system-related factors. More research is needed in this field to provide the necessary evidence for the development of early identification strategies for patients at higher risk of adverse outcomes.